Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | December 19, 2025 | December 23, 2025 |
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
| Calithera Biosciences, Inc.CALA · Entity 113073 | SR. VP & CFO | November 29, 2016 | December 01, 2016 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | June 23, 2026 | June 25, 2026 |
| Turnstone Biologics Corp.TSBX · Entity 76646 | Director | June 03, 2024 | July 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date December 19, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,563 |
Last balance in matching sequence
After 2025-12-19 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-12-19 · Sale · Disposed 2,416 · Balance 62,514 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 2 · 2025-12-19 · Sale · Disposed 5,451 · Balance 57,063 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 3 · 2025-12-19 · Sale · Disposed 500 · Balance 56,563 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
Calithera Biosciences, Inc.
Report date November 29, 2016 · Filed December 01, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2026-11-28 | Direct | 75,000 |
Reported balance
After 2016-11-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-29 · Grant · Acquired 75,000 · Balance 75,000 F1: One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
Protagonist Therapeutics, Inc
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,825 |
Ending reported balance
After 2026-06-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-23 · Exercise / conversion · Acquired 9,000 · Balance 16,825 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. Row 2 · 2026-06-23 · Sale · Disposed 9,000 · Balance 7,825 F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.54 · Expires 2030-05-27 | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-23 · Exercise / conversion · Disposed 9,000 · Balance 0 F3: These stock options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: These stock options are fully vested.
Turnstone Biologics Corp.
Report date June 03, 2024 · Filed July 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2034-06-02 | Direct | 12,770 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 12,770 · Balance 12,770 F1: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 20:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $16.54 | $0.00 |
DisclosureSEC source: 0001104659-26-077761 · tm2618679-1_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 9,000 | $117.94 | $1,061,460.00 |
DisclosureSEC source: 0001104659-26-077761 · tm2618679-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,825 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 9,000 | $16.54 | $148,860.00 |
DisclosureSEC source: 0001104659-26-077761 · tm2618679-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001553338-26-000001 · form4-06152026_040615.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $16.54 | $0.00 |
DisclosureSEC source: 0001104659-26-073049 · tm2617708-1_4seq1.xml · derivative · entry 5 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 6,000 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001104659-26-073049 · tm2617708-1_4seq1.xml · derivative · entry 4 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2029-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 9,000 | $107.68 | $969,120.00 |
DisclosureSEC source: 0001104659-26-073049 · tm2617708-1_4seq1.xml · nonDerivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,825 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $107.02 to $108.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 6,000 | $16.54 | $99,240.00 |
DisclosureSEC source: 0001104659-26-073049 · tm2617708-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,000 | $11.80 | $35,400.00 |
DisclosureSEC source: 0001104659-26-073049 · tm2617708-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001104659-26-069047 · tm2616565-1_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 9,000 | $99.64 | $896,760.00 |
DisclosureSEC source: 0001104659-26-069047 · tm2616565-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,825 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 9,000 | $11.80 | $106,200.00 |
DisclosureSEC source: 0001104659-26-069047 · tm2616565-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001104659-26-011575 · tm265544-1_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 20,000 | $83.68 | $1,673,600.00 |
DisclosureSEC source: 0001104659-26-011575 · tm265544-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,825 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.65 to $83.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 21:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 20,000 | $8.31 | $166,200.00 |
DisclosureSEC source: 0001104659-26-011575 · tm265544-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:42 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 3,762 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001478 · tm262304-7_4seq1.xml · derivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,762 Underlying: Common Stock · 3,762 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:42 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001478 · tm262304-7_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,825 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 500 | $68.53 | $34,265.00 |
DisclosureSEC source: 0001553338-25-000005 · wk-form4_1766530901.xml · nonDerivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,563 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,451 | $68.01 | $370,722.51 |
DisclosureSEC source: 0001553338-25-000005 · wk-form4_1766530901.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,063 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,416 | $66.66 | $161,050.56 |
DisclosureSEC source: 0001553338-25-000005 · wk-form4_1766530901.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,514 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:35 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001553338-25-000003 · wk-form4_1766100932.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,930 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001104659-25-099252 · tm2528674-1_4seq1.xml · derivative · entry 4 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 8,000 | $87.81 | $702,480.00 |
DisclosureSEC source: 0001104659-25-099252 · tm2528674-1_4seq1.xml · nonDerivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,130 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $86.71 to $88.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 4,000 | $69.25 | $277,000.00 |
DisclosureSEC source: 0001104659-25-099252 · tm2528674-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,130 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 12,000 | $6.98 | $83,760.00 |
DisclosureSEC source: 0001104659-25-099252 · tm2528674-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2025 Filed Sep 25, 2025 00:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 4,000 | $64.25 | $257,000.00 |
DisclosureSEC source: 0001104659-25-093046 · tm2526819-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,130 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 21:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 4,000 | $59.25 | $237,000.00 |
DisclosureSEC source: 0001104659-25-085795 · tm2524772-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,130 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:24 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001415889-25-016263 · form4-06092025_080605.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 4,000 | $54.25 | $217,000.00 |
DisclosureSEC source: 0001104659-25-025535 · tm259742-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,130 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001435 · tm252003-8_4seq1.xml · derivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001435 · tm252003-8_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 23:05 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 16,733 | $22.99 | $384,691.67 |
DisclosureSEC source: 0001628280-24-052271 · wk-form4_1734735898.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,111 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 23:19 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,747 | $22.04 | $82,583.88 |
DisclosureSEC source: 0001628280-24-051925 · wk-form4_1734563946.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,378 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 23:19 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,748 | $21.90 | $82,081.20 |
DisclosureSEC source: 0001628280-24-051925 · wk-form4_1734563946.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,125 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 23:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-24-099420 · tm2423879-1_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 23:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 8,000 | $45.00 | $360,000.00 |
DisclosureSEC source: 0001104659-24-099420 · tm2423879-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 23:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 8,000 | $12.88 | $103,040.00 |
DisclosureSEC source: 0001104659-24-099420 · tm2423879-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-24-083039 · tm2420254-1_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 8,000 | $40.00 | $320,000.00 |
DisclosureSEC source: 0001104659-24-083039 · tm2420254-1_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 8,000 | $12.88 | $103,040.00 |
DisclosureSEC source: 0001104659-24-083039 · tm2420254-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-24-070420 · tm2416932-2_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 8,000 | $35.00 | $280,000.00 |
DisclosureSEC source: 0001104659-24-070420 · tm2416932-2_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 8,000 | $12.88 | $103,040.00 |
DisclosureSEC source: 0001104659-24-070420 · tm2416932-2_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:42 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0001415889-24-016104 · form4-06082024_010625.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 03, 2024 Filed Jul 2, 2024 20:45 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | GrantStock Option (Right to Buy) · Derivative | 12,770 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001415889-24-018922 · form4-07022024_040701.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,770 Underlying: Common Stock · 12,770 shares Expires 2034-06-02 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 21:38 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | GrantStock Option (Right to Buy) · Derivative | 25,540 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001415889-24-010898 · form4-04162024_090416.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,540 Underlying: Common Stock · 25,540 shares Expires 2034-04-14 F1 · derivative.exercise_date: Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the first anniversary of the date of grant such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 12,975 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001104659-24-030157 · tm247765-2_4seq1.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,975 shares Expires 2026-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 12,975 | $31.34 | $406,636.50 |
DisclosureSEC source: 0001104659-24-030157 · tm247765-2_4seq1.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 12,975 | $6.09 | $79,017.75 |
DisclosureSEC source: 0001104659-24-030157 · tm247765-2_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,300 | $38.59 | $50,167.00 |
DisclosureSEC source: 0001628280-24-001424 · wk-form4_1705446389.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,870 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $38.32 to $39.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.